Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...

Hyku Biosciences Appoints John Gustofson to its Board of Directors John Gustofson, MS, MBA appointed to the Board of Directors The appointment is in conjunction with Chugai Venture Fund joining syndicate with an investment that brings Hyku’s total seed financing to...